325 related articles for article (PubMed ID: 24041335)
1. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
2. The expected outcome of the Trypanosoma cruzi proteomic map: a review of its potential biological applications for drug target discovery.
Menna-Barreto RF; Perales J
Subcell Biochem; 2014; 74():305-22. PubMed ID: 24264251
[TBL] [Abstract][Full Text] [Related]
3. Reevaluating the Trypanosoma cruzi proteomic map: The shotgun description of bloodstream trypomastigotes.
Brunoro GV; Caminha MA; Ferreira AT; Leprevost Fda V; Carvalho PC; Perales J; Valente RH; Menna-Barreto RF
J Proteomics; 2015 Feb; 115():58-65. PubMed ID: 25534883
[TBL] [Abstract][Full Text] [Related]
4. A proteomic analysis of the mechanism of action of naphthoimidazoles in Trypanosoma cruzi epimastigotes in vitro.
Menna-Barreto RF; Beghini DG; Ferreira AT; Pinto AV; De Castro SL; Perales J
J Proteomics; 2010 Nov; 73(12):2306-15. PubMed ID: 20621210
[TBL] [Abstract][Full Text] [Related]
5. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
6. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
7. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
8. Novel N,N-di-alkylnaphthoimidazolium derivative of β-lapachone impaired Trypanosoma cruzi mitochondrial electron transport system.
Bombaça ACS; Silva LA; Chaves OA; da Silva LS; Barbosa JMC; da Silva AM; Ferreira ABB; Menna-Barreto RFS
Biomed Pharmacother; 2021 Mar; 135():111186. PubMed ID: 33395606
[TBL] [Abstract][Full Text] [Related]
9. Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi.
Shiratsubaki IS; Fang X; Souza ROO; Palsson BO; Silber AM; Siqueira-Neto JL
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008728. PubMed ID: 33021977
[TBL] [Abstract][Full Text] [Related]
10. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
12. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
[TBL] [Abstract][Full Text] [Related]
13. Mammea type coumarins isolated from Calophyllum brasiliense induced apoptotic cell death of Trypanosoma cruzi through mitochondrial dysfunction, ROS production and cell cycle alterations.
Rodríguez-Hernández KD; Martínez I; Reyes-Chilpa R; Espinoza B
Bioorg Chem; 2020 Jul; 100():103894. PubMed ID: 32388434
[TBL] [Abstract][Full Text] [Related]
14. Major Kinds of Drug Targets in Chagas Disease or American Trypanosomiasis.
Duschak VG
Curr Drug Targets; 2019; 20(11):1203-1216. PubMed ID: 31020939
[TBL] [Abstract][Full Text] [Related]
15. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
16. Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure.
Pinto-Martinez A; Hernández-Rodríguez V; Rodríguez-Durán J; Hejchman E; Benaim G
Exp Parasitol; 2018 Jun; 189():8-15. PubMed ID: 29684665
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomics of Trypanosoma cruzi during metacyclogenesis.
de Godoy LM; Marchini FK; Pavoni DP; Rampazzo Rde C; Probst CM; Goldenberg S; Krieger MA
Proteomics; 2012 Aug; 12(17):2694-703. PubMed ID: 22761176
[TBL] [Abstract][Full Text] [Related]
18. Insights into Chagas treatment based on the potential of bacteriocin AS-48.
Martín-Escolano R; Cebrián R; Martín-Escolano J; Rosales MJ; Maqueda M; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():1-8. PubMed ID: 30953804
[TBL] [Abstract][Full Text] [Related]
19. In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi.
Timm BL; Da Silva PB; Batista MM; Farahat AA; Kumar A; Boykin DW; Soeiro MN
Parasitology; 2014 Sep; 141(10):1272-6. PubMed ID: 24735493
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease.
Hennig K; Abi-Ghanem J; Bunescu A; Meniche X; Biliaut E; Ouattara AD; Lewis MD; Kelly JM; Braillard S; Courtemanche G; Chatelain E; Béquet F
Metabolomics; 2019 Aug; 15(9):117. PubMed ID: 31440849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
